Lisata Therapeutics, Inc. (LSTA)
1.21
-0.07
(-5.47%)
USD |
NASDAQ |
Nov 13, 16:00
1.23
+0.02
(+1.65%)
After-Hours: 19:59
Lisata Therapeutics Enterprise Value : 305.79M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 305.79M |
| November 12, 2026 | 306.54M |
| November 11, 2026 | 305.68M |
| November 10, 2026 | 303.73M |
| November 09, 2026 | 304.81M |
| November 06, 2026 | 303.84M |
| November 05, 2026 | 303.43M |
| November 04, 2026 | 304.17M |
| November 03, 2026 | 304.49M |
| November 02, 2026 | 303.63M |
| October 30, 2026 | 303.73M |
| October 29, 2026 | 303.63M |
| October 28, 2026 | 304.17M |
| October 27, 2026 | 303.73M |
| October 26, 2026 | 304.17M |
| October 23, 2026 | 303.47M |
| October 22, 2026 | 303.57M |
| October 21, 2026 | 304.06M |
| October 20, 2026 | 303.95M |
| October 19, 2026 | 303.52M |
| October 16, 2026 | 303.84M |
| October 15, 2026 | 304.27M |
| October 14, 2026 | 303.73M |
| October 13, 2026 | 304.38M |
| October 12, 2026 | 304.06M |
| Date | Value |
|---|---|
| October 09, 2026 | 304.17M |
| October 08, 2026 | 305.68M |
| October 07, 2026 | 305.35M |
| October 06, 2026 | 305.79M |
| October 05, 2026 | 306.33M |
| October 02, 2026 | 308.60M |
| October 01, 2026 | 308.81M |
| September 30, 2026 | 308.27M |
| September 29, 2026 | 2.708M |
| September 28, 2026 | 2.982M |
| September 25, 2026 | 3.711M |
| September 24, 2026 | 2.982M |
| September 23, 2026 | 2.389M |
| September 22, 2026 | 2.799M |
| September 21, 2026 | 3.529M |
| September 18, 2026 | 4.805M |
| September 17, 2026 | 5.170M |
| September 16, 2026 | 2.708M |
| September 15, 2026 | 3.346M |
| September 14, 2026 | 3.529M |
| September 11, 2026 | 4.167M |
| September 10, 2026 | 4.258M |
| September 09, 2026 | 6.629M |
| September 08, 2026 | 6.264M |
| September 04, 2026 | 4.349M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.335B |
| Alnylam Pharmaceuticals, Inc. | 21.50B |
| Anika Therapeutics, Inc. | 160.67M |
| Savara, Inc. | 854.40M |
| Arrowhead Pharmaceuticals, Inc. | 6.959B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.787M |
| Total Expenses (Quarterly) | 6.787M |
| EPS Diluted (Quarterly) | -0.7294 |
| Earnings Yield | -155.7% |
| Normalized Earnings Yield | -155.69 |